Ligand Pharmaceuticals (LGND) EPS (Basic) Growth (3y) (2013 - 2026)
Ligand Pharmaceuticals (LGND) EPS (Basic) Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 53.55% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 37.73% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.29% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -2.89% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 86.43% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Ligand Pharmaceuticals | 6.05 Bn | 5.27 Bn | 48.45 Mn | -90.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -90.18% |
| Dec 31, 2025 | 147.92% |
| Sep 30, 2025 | 134.81% |
| Jun 30, 2025 | 32.26% |
| Mar 31, 2025 | -147.46% |
| Dec 31, 2024 | -133.41% |
| Mar 31, 2023 | 59.42% |
| Dec 31, 2022 | 23.30% |
| Sep 30, 2022 | 12.35% |
| Jun 30, 2022 | -2.76% |
| Mar 31, 2022 | -26.09% |
| Dec 31, 2021 | 59.47% |
| Sep 30, 2021 | -28.55% |
| Jun 30, 2021 | -28.05% |
| Mar 31, 2021 | -28.72% |
| Mar 31, 2019 | 739.90% |
| Dec 31, 2018 | -102.18% |
| Sep 30, 2018 | -31.74% |
| Mar 31, 2016 | 79.81% |
| Jun 30, 2013 | 733.97% |